• BCN Peptides put forward a new potential therapy for the treatment of inflammatory bowel disease (Crohn disease and ulcerative colitis).

    March 26, 2021


    The new therapy proposed is based on a peptide analog of Cortistatin, efficacious as anti-inflammatory and modulator of the immune response and with an improved systemic half-life with respect to the endogenous peptide.
    Its therapeutic effect was tested in several preclinical models of inflammatory bowel disease and it was even more effective than current reference treatments used clinically for these patients, such as infliximab and mesalazine.
    This work has been the result of a multidisciplinar collaboration between BCN Peptides and researchers from the Institut of Recerca Biomèdica – Barcelona and the Instituto de Parasitología y Biomedicina López Neyra – CSIC-Granada (IPBLN-CSIC).
    The results have been published in Nature Communicacions.
    https://doi.org/10.1038/s41467-021-22076-5

  • BCN PEPTIDES, a partner of the European Consortium for the use of SOLNATIDE in COVID-19 patients

    April 1, 2020


    The product Solnatide, developed by the Austrian company Apeptico Forschung und Entwicklung GmbH, is an investigational medicinal product for the treatment of various forms of life-threatening acute pulmonary dysfunction and pulmonary oedema in acute respiratory distress syndrome (ARDS) patients.

    Now, thanks to this Grant Agreement with the European Comission, Solnatide will be available for medical treatment of patients severely affected by the novel coronavirus 2019 (SARS-CoV-2) disease, COVID-19.

    In this emergency situation in hospitals across Europe, BCN PEPTIDES will manufacture Solnatide Active Pharmaceutical Ingredient for the therapeutic treatment of patients suffering from severe symptoms of infection with the SARS-CoV-2 novel coronavirus.

     

  • BCN Peptides R&D on Atopic Dermatitis  

    September 4, 2019


    BCN Peptides included Atopic dermatitis in its research program. The project, enclosed in “Nuclis d’R+D empresarial” program from ACCIÒ, is cofinanced with the European Union FEDER funds.